{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiaxp2z2d6lffe5mpsdf3no4yc7bs2powblnhezrt4dopyjp2rvosm",
    "uri": "at://did:plc:6pwit4ctv4egvys3qyqmgbi6/app.bsky.feed.post/3milla7u3k6d2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreia3skze7xchzph2zktx27npby5hnvl6pfqxjhn4vpdozwuf54jxw4"
    },
    "mimeType": "image/jpeg",
    "size": 46746
  },
  "path": "/health/breakthrough-als-study-launches-drug-aims-slow-disease-progression",
  "publishedAt": "2026-04-03T11:00:47.000Z",
  "site": "https://www.foxnews.com",
  "tags": [
    "51f17414-eef4-5033-8280-0c2278274668",
    "fnc",
    "Fox News",
    "fox-news/health",
    "fox-news/health/nervous-system-health",
    "fox-news/health/medical-research",
    "fox-news/lifestyle",
    "fox-news/health/healthy-living/medications",
    "article"
  ],
  "textContent": "The PREVAiLS study, believed to be the only recruiting phase 3 ALS trial, aims to slow disease progression and preserve function in early-stage patients.",
  "title": "Breakthrough ALS study launches as drug aims to slow disease progression"
}